Cargando…

Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects

Objective: Bococizumab, a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, has been shown to reduce low-density lipoprotein cholesterol (LDL-C). Here, we describe the pharmacokinetics and pharmacodynamics of bococizumab and its effect on lipoprotein particle composition a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokote, Koutaro, Suzuki, Akiyuki, Li, Yinhua, Matsuoka, Nobushige, Teramoto, Tamio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862531/ https://www.ncbi.nlm.nih.gov/pubmed/31549625 http://dx.doi.org/10.5414/CP203418

Ejemplares similares

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
por: Wang, Ellen Q., et al.
Publicado: (2019)

Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial
por: Bass, Almasa, et al.
Publicado: (2018)

Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject
por: Larrea-Sebal, Asier, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients
por: Fogacci, Federica, et al.
Publicado: (2022)

In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
por: Carreras, Alba, et al.
Publicado: (2019)

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　― Data From a Real-World Observational Study of Evolocumab in Japan ―
por: Yokote, Koutaro, et al.
Publicado: (2019)

Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database
por: Yokote, Koutaro, et al.
Publicado: (2021)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1
por: Chasman, Daniel I., et al.
Publicado: (2022)

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center
por: Shah, Parth, et al.
Publicado: (2016)

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012)

Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
por: Yokote, Koutaro, et al.
Publicado: (2020)

A Phase I Randomized Study of a Specifically Engineered, pH‐Sensitive PCSK9 Inhibitor RN317 (PF‐05335810) in Hypercholesterolemic Subjects on Statin Therapy
por: Levisetti, M, et al.
Publicado: (2016)

Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database
por: Shirai, Chikako, et al.
Publicado: (2021)

Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer
por: Ito, Masaaki, et al.
Publicado: (2021)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
por: Silla, Alessia, et al.
Publicado: (2023)

Effect of Black Garlic Consumption on Endothelial Function and Lipid Profile: A Before-and-After Study in Hypercholesterolemic and Non-Hypercholesterolemic Subjects
por: Villaño, Débora, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study
por: Shirai, Chikako, et al.
Publicado: (2021)

The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects
por: Acuff, Robert V, et al.
Publicado: (2007)

Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects
por: Morales, Cristian, et al.
Publicado: (2022)

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
por: Teramoto, Tamio, et al.
Publicado: (2019)

Lactic-fermented egg white reduced serum cholesterol concentrations in mildly hypercholesterolemic Japanese men: a double-blind, parallel-arm design
por: Matsuoka, Ryosuke, et al.
Publicado: (2017)

Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA Study
por: Teramoto, Tamio, et al.
Publicado: (2011)

Multidrug use positively correlates with high-risk prescriptions in the Japanese elderly: a longitudinal study
por: Arai, Sayaka, et al.
Publicado: (2019)

The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

The Effect of Temperature on the Stability of PCSK-9 Monoclonal Antibody: An Experimental Study
por: Kongmalai, Tanawan, et al.
Publicado: (2021)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Comparative pharmacokinetics of maxacalcitol in healthy Taiwanese and Japanese subjects
por: Liu, Ming-Che, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
por: Lunven, Catherine, et al.
Publicado: (2014)

Bacterial Community Profile of the Gut Microbiota Differs between Hypercholesterolemic Subjects and Controls
por: Rebolledo, Camilo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ph3q6j9m1gn339bemo0ojtqbo